News and Trends 24 Feb 2023 Beyond Biotech podcast 35: Rare Disease Day …chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own… February 24, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2022 Sanofi Joins AI Gold Rush in €4.6B Drug Discovery Pact with Exscientia …of bispecific small molecule drugs for metabolic diseases, with Sanofi in-licensing one of the candidates in 2019. As part of the new deal, Exscientia will screen patient tissue data with… January 11, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy …discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology… January 20, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 DeuterOncology closes financing round to start lung cancer study …overcomes this at source, having a metabolically-liable hydrogen replaced with a stronger bond strength deuterium atom. This significantly reduces the impact of this metabolic liability during treatment. The strength of… January 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 Meet some of the Hottest Startups of 2017! …covering neuroscience, oncology, cardiovascular and metabolic diseases, immunology, infectious diseases, vaccines and pulmonary hypertension. Chosen startups will have the opportunity to present their innovative ideas to a panel of expert… October 19, 2017 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2017 AI-Based Drug Discovery Biotech is Recruited by Sanofi in €250M Deal …believes using a bispecific drug approach that goes after more than one target can significantly increase the chances of success. Especially in metabolic diseases with high complexity such as diabetes…. May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2021 The Top European Biotech Funding Rounds in August …metabolic diseases involving the liver. And NRG Therapeutics in the UK closed a small seed investment of around £490,000 (€570,000) in a bid to treat Parkinson’s disease. One interesting seed… September 10, 2021 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies …aspects of clinical drug development. It acquires clinical-stage drugs from pharmaceutical and biotech companies and develops them. TrialSpark’s current therapeutic areas of focus include rheumatology, dermatology, CNS, and cardiometabolic diseases…. October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 5 Dec 2024 The biggest private biotech investments in November 2024 …million in series B funding. The company is focused on advancing the next generation of therapies for obesity and metabolic diseases, and the proceeds from this financing round will go… December 5, 2024 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2022 Treatment for cancer-associated thrombosis fast-tracked by FDA A clinical-stage biotechnology company that develops therapies for cardiovascular and metabolic diseases today (July 11) announced it has been granted fast track designation by the US Food and Drug Administration… July 11, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2016 Better than ADCs? AstraZeneca bids for Bicyclic Peptides …peptides, hence the company’s name, has lured AstraZeneca into offering over €1B for the development of drug candidates for respiratory, cardiovascular and metabolic diseases. Bicycles, the bicyclic peptides developed at… December 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2016 This has been the Worst Financial Year for Biotech in a Decade A presentation on the financial state of biotech kicked off BIO-Europe in Cologne this week. The hostile American political climate has done some damage. There’s a political storm brewing across… November 10, 2016 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email